Therapeutic Goods Administration An introduction to the work of Australia’s regulator of therapeutic goods.

Slides:



Advertisements
Similar presentations
And the provisions of….. the Medical Devices Regulations Medical Devices Agency.
Advertisements

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Overview of FDA Device Regulations
The regulation of medical devices in Australia. Overview Comparing medicines and medical devices What is a medical device? Statistics on patients requiring.
An introduction to the work of Australias regulator of therapeutic goods Therapeutic Goods Administration.
Postmarket monitoring. Overview What is postmarket monitoring? Why is it important? Tools used in postmarket monitoring Managing risk Adverse events 2.
Medsafe – GMP update / release for supply / communicating quality issues Derek Fitzgerald Manager, Compliance Management 11 July 2013 RACI Pharmaceutical.
By Ben Youn Copyright 2015 Quantum Business House WELCOME to QUANTUM BUSINESS HOUSE.
© Safeguarding public health Innovation; issues for regulators, society and industry. Overview of Conference topics Alasdair Breckenridge Medicines and.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Clinical Trials Medical Interventions
Introduction to Regulation
Medical Devices Approval Process
Herbal Products Presented by Janice Hermann, PhD, RD/LD
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
Personal and Consumer Health 1. Objectives 1.Demonstrate the ability to access and describe health information, health products, and health services in.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Good Manufacturing Practices for Blood Establishments
+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.
Weaving regulations into sound value analysis processes Barbara Strain, MA, SM(ASCP) Director Value Management University of Virginia Health System.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Essential Question: How are clinical trials set up to ensure all data collected is valid and that all human subjects are treated ethically?
“Put the Power of Predictive Analytics in the Hands of Clinical Researchers” Filippos Katsampouris Marketing Manager Healthcare & Pharmaceutical Accounts.
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
Lecture Nineteen Biomedical Engineering for Global Health.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
From the Lab to Market Unit 3.04 Understanding Biotechnology research & Development.
Changes to the Therapeutic Goods Act and its implications Prepared by: Anna Frazer Prosthetist Hunter Prosthetics & Orthotics Service 10 th November 2006.
FDA Focus On Consumer Protection
Food safety and quality legislation Chapter 8. FSANZ The federal government have a responsibility in ensuring Australian’s have a safe food supply. The.
NRA in BTSs of the EMR Dr. Nabila E. Metwalli Regional Advisor / Blood Safety WHO / EMRO Cairo, Egypt and Dr. Abdel Aziz Saleh WHO / EMRO Advisor.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.
Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
© Safeguarding public health Can Europe grow its Medtech industry and lead the world on medical device regulation? John Wilkinson 20 th September 2012.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
Jamie Bango Lindsey Croker Kristen Lantz Achidi Ndiforchu.
Purpose of Clinical Trials Assess safety and efficacy of Experimental treatments New combinations of drugs New approaches to surgery or radiation therapies.
Medsafe and Therapeutic Product Advertising Update Derek Fitzgerald Manager, Compliance Management 5 November 2014 TAPS Industry Briefing - Auckland.
1 CHALLENGES IN REGULATING QUALITY AND RATIONAL USE OF ANTIBIOTICS ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS: INAGURAL MEETING COURTYARD.
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
The Regulation on Cell Therapy Products in Japan
Collaborative Institutional Training Initiative (CITI) citiprogram.org Georgia Institute of Technology.
PD233: Design of Biomedical Devices and Systems (Lecture 2) Dr. Manish Arora CPDM, IISc Course Website:
Drug Development Process Stages involved in Regulating Drugs
Executive Director, Registrar Corp
List of contents: TGA What is TGA ? Objective of TGA Role of TGA
Guidance for review of studies involving HCT/Ps and IND Basics
Reforms to Support Safe and Timely Access to Medicines
Clinical Trials — A Closer Look
FDA Perspective on Cardiovascular Device Development
Clinical Trials Medical Interventions
Introduction to Clinical Pharmacy
CDRH 2010 Strategic Priorities
Get Ready for FDA Oversight of Laboratory Developed Tests Presenter:
Clinical Trials.
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
Medical Devices.
Patient Involvement in the Development and Safe Use of
MEDICAL DEVICES CONTROL SYSTEM IN INDONESIA
Therapeutic Products Bill-consultation phase
Compounded Drugs and Lack of Premarket FDA-Approval
Presentation transcript:

Therapeutic Goods Administration An introduction to the work of Australia’s regulator of therapeutic goods

Overview Why do we need regulation? Who is Australia’s regulator? How the TGA operates Who works at the TGA Therapeutic goods Australian Register of Therapeutic Goods TGA’s mission The benefit versus risk approach Activities conducted before and after a product is released to the market Other education modules 2

Why do we need regulation? Australian doctor William McBride alerted the world to the dangers of thalidomide in the 1960s which triggered the need for an Australian regulator of therapeutic goods. “In recent months I have observed that the incidence of multiple severe abnormalities in babies delivered of women who were given the drug thalidomide (‘Distival’) during pregnancy, as an anti-emetic or as a sedative, to be almost 20%.” 3

Who is Australia’s regulator? The Therapeutic Goods Administration was established in 1990 to “safeguard and enhance the health of the Australian community through effective and timely regulation of therapeutic goods” It provides a national system of controls relating to the quality, safety, efficacy and timely availability of therapeutic goods used in, or exported from, Australia Health Safety Regulation 4

TGA – how we operate We are part of the Australian Government Department of Health Every decision the TGA makes is based on the Therapeutic Goods Act 1989 Main offices in Canberra – satellite offices in Sydney, Melbourne, Adelaide and Brisbane Operations are primarily cost recovered (98%) industry pays fees for making applications and annual charges for products they are responsible for 5

Who works at the TGA? Approximately 750 staff made up of: Biomedical scientists EngineersPhysiotherapistsMedical officers PharmacistsNursesToxicologistsLawyers NutritionistsDieticiansScientists Administrative staff 6

Under the Therapeutic Goods Act 1989, therapeutic goods are defined as: Products for use in humans in connection with preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury influencing, inhibiting or modifying a physiological process testing the susceptibility of people to a disease or ailment influencing, controlling or preventing conception testing for pregnancy replacing or modifying parts of the anatomy All these products are therapeutic goods! 7

Types of therapeutic goods Medicines and blood products prescription medicines over-the-counter medicines complementary medicines blood, blood components and plasma derivatives Medical devices implants (artificial hips, breast implants) in-vitro diagnostics (pregnancy tests, blood glucose monitors) low risk medical devices (bandages, tongue depressors, condoms) Biologicals human stem cells tissue-based products (skin and bone) cell-based products 8

Australian Register of Therapeutic Goods All goods must be entered in the ARTG before they can be supplied in, imported to, or exported from AustraliaARTG higher risk medicines that are registered on the ARTG evaluated for quality, safety and efficacy Product Information is approved by the TGA All prescription medicinesprescription medicines Most over-the-counter medicinesover-the-counter medicines Some complementary medicinescomplementary medicines lower risk medicines that are listed on the ARTG contain pre-approved, low risk ingredients can only make limited claims and cannot imply that they will be useful in the treatment or prevention of serious illnesses Some over-the-counter medicinesover-the-counter medicines Most complementary medicinescomplementary medicines higher risk devices are evaluated for quality, safety and performance lower risk devices are not evaluated for performance Devices are classified according to their level of risk, ranging from Class I (lower risk) such as urine collection bottles to Class III (higher risk) such as antibiotic bone cements Registered medicinesListed medicinesMedical devices 9

TGA’s mission To safeguard and enhance the health of the Australian community through the effective and timely regulation of therapeutic goods. Health Safety Regulation 10

How do we fulfil this mission? Good Manufacturing Practice or Manufacturing Principles: licensing Australian manufacturers and verifying compliance of overseas manufacturers (see the TGA education module on GMP) Premarket assessments: assessing therapeutic goods for quality and safety (the extent of the assessment depends on the type of product and level of associated risk), and for higher risk products also for efficacy or performance Postmarket assessments: monitoring of therapeutic goods and enforcement of standards (see the TGA education module on postmarket monitoring) 11

The benefit versus risk approach No therapeutic good is risk free The work of the TGA is based on applying scientific and clinical expertise to decision making We ensure that the benefits outweigh any risks associated with the use of medicines, medical devices and other therapeutic goods 12

Premarket assessment The level of assessment is based on how much risk the product poses Low risk Products such as complementary medicines and low risk medical devices are assessed for quality and safety High risk Products such as prescription medicines are assessed for quality, safety and efficacy High risk medical devices are assessed for quality, safety and performance For both categories there are manufacturing standards that must be met 13

Postmarket activities Monitoring/Alerts Monitors claims made in advertisements for therapeutic goods and issues fines and sanctions if they can not be supported Issues alerts Databases Records reports of adverse events by consumers, health professionals and industry Records recall actions Manufacturing Further inspections of manufacturers of therapeutic goods 14

Other education modules include: Medicines Biologicals Medical devices Postmarket monitoring Good Manufacturing Practice 15